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not use quality-adjusted life years (QALYs) in its efficiency frontier approach to
pharmacoeconomic evaluation. The lack of a global measure of effectiveness
across indications is subject to criticism by international experts. In response,
IQWiG refers to German legal restrictions. The objective of this analysis is to ex-
amine whether German legislation allows the use of QALYs in pharmacoeconomic
evaluation.METHODS:We employ a legal analysis of German legislation concern-
ing the provisions relevant to pharmacoeconomic analysis by IQWiG. Our analysis
includes specific pharmacoeconomic provisions, constitutional restrictions and
jurisdiction. RESULTS: According to German Social Code Book V, IQWiG’s phar-
macoeconomic evaluation is to be based on international standards. This could
hint at the NICE’s use of QALYs if the existence of an international standard is
assumed in the first place. The Federal Constitutional Court of Germany, however,
has consistently stressed life and health as most important fundamental rights in
the German constitution. German jurisdiction has interpreted the German consti-
tution as prohibiting putting amonetary value on life or health. However, the global
use of QALYswould imply putting an explicit or implicit threshold value on aQALY,
i.e. a value on life and health. Therefore, IQWiG’s reluctance to use QALYs in its
method is justified by legal restrictions as imposed by the German constitution.
CONCLUSIONS: Our analysis shows that English standards cannot be adopted
without considering legal restrictions in the German context. These restrictions
prohibit the use of QALYs. The use of QALYs is motivated by the assumption of a
fixed health care budget. The German legislator confirmed its rejection of this
assumption by increasing Statutory Health Insurance contributions from 14.9 % to
15.5 %, effective January 2011.
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PHARMACOECONOMICS IN REPUBLIC OF KAZAKHSTAN
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OBJECTIVES: Analysis of pharmacoeconomic studies (FES), held in the Republic of
Kazakhstan between 2005 and 2010. METHODS: Produced an information search
using keywords pharmacoeconomics, clinical and economic analy-
sis. It was analyzed 81 scientific researches of national researchers which was
published in the republican (national) publications. RESULTS: Among the papers
was dominated pharmacoeconomic studies (FES) in the therapeutic (bronchial
asthma, COPD, hypertension, peptic ulcer, etc.) and psychiatric practice (mostly -
Pharmacoeconomics of neuroleptics). Studies of the clinical and economic aspects
for health technology assessments are not found. Selection of FES carried proac-
tive. Among the methods of pharacoeconomic analysis (FEA) the most frequently
used analysiswascost of disease. Cost-effectiveness analysiswas used in 23
(28%) studies. Incremental analysis was performed only in 2 FES. Analysis of the
costminimizationwas usedmethodologically correct only in 2 papers.Mod-
eling in the FES was used in 10 (12%) studies. Another 6 (0.7%) works extrapolated
the results of foreign researchers, taking into account the national clinical practice.
Others were presented reviews of popularization of pharmacoeconomics, ABC and
VEN-analysis of various medical organizations. CONCLUSIONS: In Republic of Ka-
zakhstan pharmacoecnomics is at an early stage of development. There is a need to
update and deploy the FES on the background of the proper use themethodology of
pharmacoeconomics, the definition of a coordinator and a real consumer FES, im-
provement of legislation provision for such research.
Research on Methods – Databases & Management Methods
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IS IT FEASIBLE TO COLLECT QUALITY OF LIFE DATA ELECTRONICALLY IN THIN -
A UK GENERAL PRACTICE DATABASE?
Blak BT, Lee J, Thompson M, Bourke A, Pinder L
Cegedim Strategic Data Medical Research Ltd, London, UK
OBJECTIVES: Quality of life (QoL) information is increasingly used in research. This
pilot study evaluated the feasibility of collecting electronic QoL data in UK general
practices that can be linked to patients’ anonymous electronic medical records.
METHODS: Patients18 years who visited one of three practices contributing data to
The Health Improvement Network (THIN) database during a 31-day period were in-
cluded. Patients were asked to complete an experimental electronic questionnaire
based on the EQ5D questionnaire and EQ5Dvas (Visual Analogue Scale) on a personal
digital assistant (PDA) (PocketVision, Inchware).Datawereanalysedandeachpractice
was interviewedshortly after studyend for feedback.Acceptability ratewasdefinedas
thepatients completing thequestionnairedividedby thepatientsasked toparticipate;
feasibility rate was the proportion of visiting patients asked to participate. RESULTS:
In total, 177 of 5058 visiting patients, were asked to participate with mean age 47.6
years (standard deviation (SD):17.7) versus 51.6 years (SD:19.0) (p-value0.003) for pa-
tients not asked (n4881). The overall acceptability rate was 93.2% (164/176, one pa-
tient excluded as recorded as both accepted and declined). Mean age for patients
completing the questionnaire was 47.0 years (SD:17.3) versus 51.0 years (SD:17.1) for
patients declining (p-value0.447). There was no difference between genders. The
overall feasibility rate was 3.5%(177/5058): 10.1%(94/929) for Practice-1, 1.1%(16/1529)
for Practice-2, 2.6%(67/2600) for Practice-3. Practices suggested that multiple PDAs
could have been helpful and it was time-consuming to monitor the PDA; however,
they preferred the electronic method over paper questionnaires and were happy to
repeat the experiment. CONCLUSIONS: The high acceptability rate suggests that pa-
tients are prepared to provide electronicQoL data. Thismay also be owing to practices
targeting younger patientswho appearmore familiarwith electronic devices. Though
feasibility ratesdifferedacrosspractices, allwerewilling to takepart again, supporting
electronic QoL data collection.
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OBJECTIVES: Naïve Bayesian networks are used in syndromic surveillance to clas-
sify emergency department chief complaints into disease syndromes and detect
outbreaks in an automated real-time manner. Study objectives were to develop a
modified Bayesian classifier and compare its performance to the naïve Bayesian
classifier. METHODS: Data from the Real-time Outbreak and Disease Surveillance
(RODS) system containing 1000 chief complaints were classified into one of 8 syn-
drome classifications (Gastrointestinal, Constitutional, Respiratory, Rash, Hemor-
rhagic, Botulinic, Neurological, and Other) by a physician. All algorithms in the
studywere comparedwith this standard. The datawere used to develop, train, and
test the naïve and modified Bayesian networks. For each chief complaint, the syn-
drome classification was predicted by using all other chief complaints in the data
set to train the Bayesian network and calculate prior probabilities. Multinomial
logistic regression (MNL) and Classification and Regression Trees (CART) models
were also examined to provide benchmark measures of performance. Kappa sta-
tistics and p-values were calculated. RESULTS: The data set contained only 1 chief
complaint for the Botulinic syndrome, which was consequently excluded from the
study. The remaining 999 chief complaints and 7 syndrome classifications were
used to develop and estimate the models. To simplify the statistical analysis, 68
chief complaints with more than one classification were excluded, resulting in a
total of 931 chief complaints. Kappa statistics for the naive Bayesian network
(©0.85), modified Bayesian network (©0.85), CART (©0.83) and MNL
(©0.86) indicate that all classifiers perform similarly compared to expert classi-
fication (p 0.01 for all kappa statistics). CONCLUSIONS: All methods performed
similarly, suggesting that choice of algorithm in syndrome classification does not
really matter. The CART approach may be preferred over the Bayesian or logistic
approaches as it is rule-based and, therefore, can be easily implemented in virtu-
ally any electronic health record system.
Research on Methods – Modeling Methods
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O’Mahony J, van Rosmalen J
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OBJECTIVES: To demonstrate that differential discounting can confuse comparisons
of cost-effectiveness between interventions. In particular, to show that directly com-
paring cost-effectiveness ratios of different interventions from conventional cost-ef-
fectiveness models can result in misleading cost-effectiveness rankings under differ-
ential discounting. METHODS: A simple example of a comparison of the cost-
effectiveness of two hypothetical interventions is used. The first intervention is a
once-off vaccination, which imposes costs in one year alone per patient-cohort. The
second intervention is a therapy for a chronic condition, which imposes costs for
many consecutive years per patient-cohort. Both interventions are assessed on the
conventional basis of a single cohort of patients, resulting in cost-effectiveness esti-
mates for each intervention, which are then compared. An alternative comparison of
cost-effectiveness is then made; it considers the opportunity cost of adopting the
therapy for one cohort of patients in terms of the vaccination that could be provided
for many cohorts over the same period. This alternative comparison yields a second
pair of cost-effectiveness ratios which are compared to those from the conventional
per cohort comparison. RESULTS: Comparing the interventions on the basis of the
actual opportunity cost with the same distribution of spending over time shows the
vaccination to be relatively more cost-effective than under the conventional per co-
hort analysis. Furthermore, the alternative comparison shows the two interventions
to have the same relative cost-effectiveness as if the conventional per cohort compar-
ison had been undertaken with discount rates unadjusted for growth in the cost-
effectiveness threshold (equal discounting). CONCLUSIONS: The debate over differ-
ential discounting has not considered the practical implications for decision making.
Our analysis shows that accounting for threshold growth using differential discount-
ing can make comparisons from conventional forms of cost-effectiveness analysis
misleading as to which interventions are most cost-effective. Accounting for thresh-
old growth using differential discounting is less relevant for decision making than
previously understood.
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Anaya P
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OBJECTIVES: To develop an instrument to assess usefulness of any given simulation
software in theHealth Economics (HE) field and to create a list of available software for
modeling.METHODS: A continued Internet search for available open source or com-
mercial discrete events simulation (DES) software that could be used in the HE field
was performed for four years. Selection of packages included in this study was based
either in having animation or amodule based programming or becausemodels could
beuploaded andaccessed through Internet. Amoredetailed comparison (building the
same model) was made between TreeAge ProSuite, Arena-Basic, Simul8-Basic and
Simul8-Professional with an instrument designed by the author specifically for this
reason including 22 items grouped in three categories: 1) Processing capacity and ease
of use; 2) Adaptability to HE; 3) Transparency and capacity to self-explain. Other pack-
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ages mentioned below were not measured with this instrument due to lack of hands
on experience by the author. TreeAge ProSuite was included as a gold standard com-
parator forHE. A Linkert scale (1 to 5)was used to grade each item.RESULTS: Thirteen
packages were found and considered in this review. Among the best software (in-
cluded two or three characteristics of the selection criteria) suitable for HE modeling
were AnyLogic, Arena, SAS Simulation Studio, Simio, Simul8 and TreeAge. Average
grades (ordered from less expensive tomost expensive)were as follows: Simul8-Basic,
3.89; TreeAge ProSuite, 3.07; Arena-Basic, 3.00; Simul8-Professional, 4.43.
CONCLUSIONS: This work tried to create a list of items to objectively measure the
characteristics of HE modeling software. At this point results of the graded packages
represent theviewsof theauthor. This instrumentmaybeauseful toolwhendeciding
between different packages to buy. Future work is required for this instrument to be
assessed by other modeling experts.
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VALIDATING AN ONLINE CALCULATOR FOR EVALUATING HEALTH
INTERVENTION OPTIONS USING THE ANALYTIC HIERARCHY PROCESS (AHP)
McGhan WF, Vichaichanakul K, Willey VJ
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OBJECTIVES: To evaluate an online calculator for analyzing and scoring health
intervention options using the analytic hierarchy process (AHP).METHODS:Aweb-
based calculator was developed that generates priority scores using the Analytic
Hierarchy Process as well as various AHP statistics and graphs. AHP is designed to
assist in decision-making situations involving multiple attributes by making judg-
ments about the relative importance of key attributes and then specifying a pref-
erence for each decision alternative on each attribute. The web-based software is
freely available at: www.healthstrategy.com (HDS). The tool was compared to an
MS Excel calculator from K. Teknomo which can be downloaded from: http://peo-
ple.revoledu.com/kardi/tutorial/AHP. These two software options were evaluated
against results from a published health economics paper from Nuijten and Kosa
that utilized AHP on three antidepressant choices around the threemain factors of
budget impact, therapeutic value, and cost effectiveness. RESULTS: The published
paper results compared with the Teknomo and HDS calculators were as follows on
factor weights: Budget Impact (0.28, 0.28, 0.28), Cost Effectiveness (0.07, 0.07, 0.07),
Therapeutic Value (0.65, 0.64, 0.64). On overall score (composite weights) the pub-
lished paper compared with the Teknomo and HDS calculators as follows: New
Drug (0.49, 0.56, 0.56), SSRI (0.26, 0.18, 0.18), TCA (0.25, 0.26, 0.26). CONCLUSIONS:
Both software approaches provided basic statistics and graphs often found in AHP
reports. For basic scoring, the HealthStrategy and Teknomo approaches provided
similar results, but differed somewhat from the published paper that used addi-
tional sub-factors on some attributes. For future research, additional datasets
should be explored, sensitivity analyses should be performed on key variables, and
comparisons should be made with more comprehensive software and multi-attri-
bute utility approaches.
Research on Methods – Patient-Reported Outcomes Studies
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ADHERENCE IS ADHERENCE IS ADHERENCE: THE CONSISTENCY OF MORISKY
ADHERENCE SCORES ACROSS THE COSTLIEST CHRONIC CONDITIONS
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OBJECTIVES: Patient non-adherence to prescribed therapies has been shown to be
associated with worse health outcomes. However, it is unclear the extent to which
adherence varies as a function of the condition versus the patient. The aim of this
study was to investigate the consistency of adherence scores across the costliest
chronic conditions in the U.S.METHODS: Data from the 2010 U.S. National Health
and Wellness Survey (NHWS) were used. Included for analysis were only those
patients (N32,636) who reported using a medication for their asthma, pain, con-
gestive heart failure (CHF), COPD, diabetes, hypertension, depression, bipolar dis-
order, peripheral vascular disease (PVD), transient ischemic attack (TIA), or stroke.
Adherence, measured using the four-item Morisky Medication Adherence Scale
(MMAS), was assessed separately for each condition. Health utilities were also
assessed using the SF-12v2. RESULTS: Among patients taking prescription medi-
cation for asthma (n4,786), pain (n8,984), CHF (n905), COPD (n1,664), diabetes
(n7,065), hypertension (n19,475), depression (n7,850), bipolar disorder
(n1,425), PVD (n163), TIA (n437), or stroke (n507), 48.9% were male, 79.3%
were white, and mean age was 54.9 years (SD15.3). Across all conditions, high
internal consistency was observed for total MMAS scores (Cronbach’s a0.97) and
all MMAS items (“careless about taking medications”, a0.97; “stop taking medi-
cations when feeling better”, a0.94; “stop taking medications when feeling
worse”, a0.96; and “forgetting to take medications”, a0.97). Number of respon-
dents sharing any two conditions ranged from n9 to n4563, yet MMAS total
score correlations across any two conditions were all significant, ranging from
r0.41 to r1.00.With the exception of pain, non-adherencewithin each condition
was associated with lower health utilities (though not always significantly:
r0.02 to r0.12).CONCLUSIONS: The results suggest that adherence is a stable
construct, consistent from condition to condition for each patient. Non-adherence
on one therapy may be an indicator of non-adherence on another therapy.
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OBJECTIVES: Previous researchers (Ren, 1999) have used a 5-item shortened ver-
sion of the Medical Outcomes Study Social Support Scale (MOS-SSS; Sherborne,
1991), but the measurement properties of this brief measure have not been estab-
lished. We filled this gap by evaluating the psychometric properties of a 5-item
perceived social support instrument (the SS-5) and testing equivalence between
paper and web-based administration modes.METHODS: The SS-5 and other ques-
tionnaire measures were administered to a sample of adults recruited through
newspaper and web-based advertisements in 8 US cities. Participants were ran-
domized to complete the SS-5 on either paper or computerized format followed by
a one-week retest. The intraclass correlation coefficient (ICC) was calculated to
assess reproducibility of the SS-5 and equivalence between administrationmodes.
Cronbach’s alpha was calculated to assess internal consistency. To assess known
groups’ validity, differences in SS-5 scores between marital status/living arrange-
ment groups and (separately), trichotomous groupings of a validated measure of
dispositional optimism, the Life Orientation Test (LOT-R), were assessedwith anal-
ysis of variance (ANOVA)models. RESULTS:Of the 258 participants that completed
the baseline assessment, 251 (97%) completed the retest. Mean age of participants
was 48.6 years, 61% were female, and 71% were Caucasian. Participants included
44% married or living with a partner; 24% had never been married. The mean SS-5
scorewas 17.34.9, and the ICC between paper andweb-basedwas 0.89. Reproduc-
ibility was strong (ICC0.92), and the instrument was internally consistent (al-
pha0.88). The SS-5 significantly discriminated between participants living with a
partner and those living alone (means: 19.1 vs. 15.9; p0.001) and tertiles of the
LOT-R. The correlation of SS-5 scores to the full MOS-SSS was 0.91. CONCLUSIONS:
The SS-5 was observed to have adequate reproducibility and internal consistency;
and demonstrated appropriate known groups validity. Equivalence between paper
and web-based administration was demonstrated.
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DEVELOPMENT AND VALIDATION OF A HEALTH RELATED QUALITY OF LIFE
INSTRUMENT TO MEASURE THE IMPACT OF OVER-THE-COUNTER PRODUCT
USE AND ASSOCIATED ADVERSE EVENTS
Chopra P, Patel H, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: A self-administered questionnaire was developed to evaluate health
related quality of life (HRQoL) with over-the-counter (OTC) product use and HRQL
with OTC product use associated adverse drug events (ADRs). Validity and reliabil-
ity was assessed to determine psychometric properties of these new instruments.
METHODS: The questionnaire was developed as part of a cross sectional study in
an elderly population and included content based on existing literature and dis-
cussionswith expert panel. HRQoLOTC product use scale (9 items) andHRQoLOTC
ADR scale (9 items) was measured using a 5-point Likert scale (strongly agree to
strongly disagree). The questionnaire was tested on a pilot sample to evaluate
legibility, response burden, and comprehension. Seniors residing in retirement
homes or visiting senior community centers and using OTC products participated.
Reliability was evaluated on the basis of internal consistency. Concurrent validity
was evaluated by comparing scores obtainedwith an existing general health status
measure (GHS). Data were collected and analyzed using SAS v9.2. RESULTS: A total
of 157 seniors completed the survey yielding a response rate of 66.5%. The mean
age of the sample was 75.1(4.7) years with majority being male (56.2%) and white
(67.5%). Of the total sample, 22.9% had an adverse event due to OTC use. The
reliability coefficient was very high for the two scales, namely, HRQL OTC product
use scale (0.95) and HRQoL OTC ADR scale (0.92), with mean summary scores of
3.60.8 and 2.50.6, respectively. The GHS measure was significantly correlated
with HRQoL OTC product use (r0.3, p0.0001) and HRQoL OTC ADR (r 0.5,
p0.01) scores. In addition, both scales were significantly correlated with each
other (r0.7, p0.0001). CONCLUSIONS: Both scales exhibit excellent reliability
and evidence of validity. Further, assessment using other products and different
populations would help increase generalizability of these instruments.
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CAN UTILITIES EXCEED 1.0? EMPIRICAL EVIDENCE OF THE CEILING EFFECT
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OBJECTIVES: There is some debate about whether utilities can exceed 1.0. This
assumption has important ramifications regarding which statistical methods are
appropriate. It is convention that utilities are anchored at 0.0 (death) and 1.0 (full
health). The descriptive health state corresponding to ‘full health’ differs across
instruments. The objective of this research is to examine the extent to which the
value for ‘full health’ differs between the SF-6D and the EQ-5D and to explore the
existence of a ceiling effect for utilities.METHODS: The 2000-2003 Medical Expen-
diture Panel Survey was used to estimate predicted SF-6D and EQ-5D (UK) scores
using Tobit, CLADandOLS regressions. EQ-5D (and SF-6D) scoreswere regressed on
SF-12 scores and sociodemographic characteristics. The regression equationswere
then used to predict EQ-5D and SF-6D scores. The two series of predicted scores
were compared to examine ceiling and floor effects. RESULTS: 47% of individuals
had a score of 1.0 on the EQ-5D and only 7% on the SF-6D. The SF-6D exhibited
significant floor effects with the lowest value at 0.344 compared to 0.594 for the
EQ-5D. Based on the Tobit predicted scores, a value of 1.0 on the SF-6D corre-
sponded to a value of 1.2 on the EQ-5D. This result suggests that a large portion of
the 46% of individuals with a score of 1.0 on the EQ-5D would actually have utility
scores greater than 1.0 on a scale without such a pronounced ceiling effect. Like-
wise a 0.34 on the SF-6D corresponded to 0.03 on the EQ-5D, suggesting a floor effect
for the SF-6D. CONCLUSIONS: Statistical estimation should incorporate censored
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